QVCGA Q3 2025 Earnings Significant Loss Reported No Consensus Estimate Available EPR Properties Q1 2026 Earnings EPS Surges Past Expectations Amid Strong Experiential Demand IVVD Q1 2026 Earnings EPS Misses Estimates as PreRevenue Biotech Focuses on Pipeline Progress ANRO Q1 2026 Earnings Significant EPS Miss Highlights EarlyStage Development Costs Waldencast WALD Q4 2024 Earnings Significant EPS Miss Reflects Persistent Operational Challenges RCKT Q1 2026 Earnings EPS Misses Estimates as PreRevenue Biotech Continues Clinical Progress